CONCLUSION
Accidental over-dosage remains a cause of concern with anticipated increase in the use of HU, especially the sweet compounded formulations. This calls for parental education on proper drug storage and use of child-safety caps. Limiting prescriptions of compounded formulations to a two-week supply will reduce the likelihood of any substantial large overdose. Temporary cessation of therapy, close observation and monitoring for myelosuppression for about four weeks should be adequate intervention for most instances of overdosage in young children with SCA.
Declaration of interests: None